Does the Spectrum model accurately predict trends in adult mortality? Evaluation of model estimates using empirical data from a rural HIV community cohort study in north-western Tanzania

Denna Michael, Chifundo Kanjala, Clara Calvert, Carel Pretorius, Alison Wringe, Jim Todd, Balthazar Mtenga, Raphael Isingo, Basia Zaba & Mark Urassa

To cite this article: Denna Michael, Chifundo Kanjala, Clara Calvert, Carel Pretorius, Alison Wringe, Jim Todd, Balthazar Mtenga, Raphael Isingo, Basia Zaba & Mark Urassa (2014) Does the Spectrum model accurately predict trends in adult mortality? Evaluation of model estimates using empirical data from a rural HIV community cohort study in north-western Tanzania, Global Health Action, 7:1, 21783, DOI: 10.3402/gha.v7.21783

To link to this article: https://doi.org/10.3402/gha.v7.21783

© 2014 Denna Michael et al. Published online: 16 Jan 2014.

Submit your article to this journal

Article views: 62

View related articles

View Crossmark data

Citing articles: 1 View citing articles
Does the Spectrum model accurately predict trends in adult mortality? Evaluation of model estimates using empirical data from a rural HIV community cohort study in north-western Tanzania

Denna Michael1*, Chifundo Kanjala1,2, Clara Calvert2, Carel Pretorius3, Alison Wringle2, Jim Todd1,2, Balthazar Mtega1, Raphael Isingo1, Basia Zaba2 and Mark Urassa1,2

1Sexual and Reproductive Health Program, National Institute for Medical Research-Mwanza Center, Mwanza, Tanzania; 2Department of Population Health, London School of Hygiene and Tropical Medicine (LSHTM), London, UK; 3Futures Institute, Glastonbury, CT, USA

Introduction: Spectrum epidemiological models are used by UNAIDS to provide global, regional and national HIV estimates and projections, which are then used for evidence-based health planning for HIV services. However, there are no validations of the Spectrum model against empirical serological and mortality data from populations in sub-Saharan Africa.

Methods: Serologic, demographic and verbal autopsy data have been regularly collected among over 30,000 residents in north-western Tanzania since 1994. Five-year age-specific mortality rates (ASMRs) per 1,000 person years and the probability of dying between 15 and 60 years of age (45Q15) were calculated and compared with the Spectrum model outputs. Mortality trends by HIV status are shown for periods before the introduction of antiretroviral therapy (1994–1999, 2000–2005) and the first 5 years afterwards (2005–2009).

Results: Among 30–34 year olds of both sexes, observed ASMRs per 1,000 person years were 13.33 (95% CI: 10.75–16.52) in the period 1994–1999, 11.03 (95% CI: 8.84–13.77) in 2000–2004, and 6.22 (95% CI: 4.75–8.15) in 2005–2009. Among the same age group, the ASMRs estimated by the Spectrum model were 10.55, 11.13 and 8.15 for the periods 1994–1999, 2000–2004 and 2005–2009, respectively. The cohort data, for both sexes combined, showed that the 45Q15 declined from 39% (95% CI: 27–55%) in 1994 to 22% (95% CI: 17–29%) in 2009, whereas the Spectrum model predicted a decline from 43% in 1994 to 37% in 2009.

Conclusion: From 1994 to 2009, the observed decrease in ASMRs was steeper in younger age groups than that predicted by the Spectrum model, perhaps because the Spectrum model under-estimated the ASMRs in 30–34 year olds in 1994–99. However, the Spectrum model predicted a greater decrease in 45Q15 mortality than observed in the cohort, although the reasons for this over-estimate are unclear.

Keywords: HIV; adult mortality; Spectrum model; cohort

*Correspondence to: Denna Michael, National Institute for Medical Research (NIMR), Mwanza Medical Research centre, PO Box 1462, Isamilo Road, Mwanza, Tanzania, Email: dennamichael@gmail.com or dmichael78@yahoo.com

A Corrigendum has been published for this paper. Please see http://www.globalhealthaction.net/index.php/gha/article/view/24079

This paper is part of Special Issue “Measuring HIV associated mortality in Africa”. More papers from this issue can be found at http://www.globalhealthaction.net

Received: 18 June 2013; Revised: 29 November 2013; Accepted: 10 December 2013; Published: 16 January 2014

Tanzania, like many other sub-Saharan African countries, has experienced high adult mortality due to HIV/AIDS. The adult mortality rate is the probability of dying between age 15 and 60 years and is known to demographers as 45Q15. In Tanzania 45Q15 was estimated as 45% in 1995, 45% in 2000, and 40% in 2005 (1), but in a study in northern Tanzania in 1999, the 45Q15 was estimated as 49% for men and 46% for women (2). There is strong evidence that all-cause, adult mortality rates elsewhere in East Africa have declined over the past
10 years, with Uganda showing that all-cause adult mortality declined by 25% following the roll-out of anti-retroviral therapy (ART) (3). Other sites in Africa compare all-cause adult mortality 2–6 years following ART roll-out with pre-ART period and show a decrease of 42% in Karonga, Malawi; 21% in Kisesa, Tanzania; and 21% in UMkhanyakude, South Africa (4), although the overall pattern in South Africa may not show much decrease in all-cause adult mortality (5). However, HIV is still a leading cause of adult death in many countries in East and Southern Africa (6).

In Tanzania in 1996, in a population aged 15–54 years with a 4% prevalence of HIV, 35% of all deaths occurred in HIV positives (7). In Zambia in 1999 in two townships with a 15% prevalence of HIV among adults, 53% of all deaths were attributable to HIV (8) while in Zimbabwe, in 2006, 61% of all adult deaths were attributable to HIV (9). However, HIV-attributable mortality has declined in Tanzania since 2004 (C. Kanjala et al., unpublished data), and the most obvious reason for the decline in all-cause and HIV-attributable mortality is the availability of ART (10).

Due to the weaknesses in vital registration and health information systems in developing countries, little information is available for planning of health services. National and regional health planners depend on estimates and projections from demographic and epidemiological models. Even if there were reliable demographic data in these countries, good, validated models would be needed to study the potential impact of health interventions. The Spectrum model, developed by the Futures Institute, uses information from national or sentinels, population-based surveys, in order to estimate key parameters of the HIV epidemic (11, 12). Estimating HIV incidence from prevalence relies on an accurate progression and survival model for HIV, which has thus far been validated against a limited number of data sets. Problems with data quality and model specification can lead to incorrect projections. Demographic surveillance sites that also collect HIV data can be used to verify the model specification, and validate the out-parameters of the Spectrum model, thus improving the model fit, and the understanding of the HIV epidemic curves applied to the data.

This paper describes trends and patterns in age-specific mortality rates (ASMRs) and in the index of adult mortality (45Q15) in Kisesa HIV cohort study in north-western Tanzania from 1999 to 2009. The paper then compares these observed mortality rates and 45Q15 with estimates from the Spectrum model.

Methods

Population data
The Kisesa HIV cohort study is based on the population of seven villages located approximately 20 km east of Mwanza City in north-western Tanzania. The seven villages range from urbanised, roadside settlements near the ward’s trading centre to remote rural settlements, with 95% of the population belonging to the Sukuma tribe, the largest ethnic group in Tanzania. The main economic activities are small-scale farming and petty trade of both agricultural and livestock products, while a minority of residents are fishermen. The demographic surveillance system (DSS) conducts a household count every 3–6 months to record new residents through births and in-migration, as well as those lost to the cohort through death and out-migration. The DSS began in 1994, with a population of 19,350, and by 2011 the population had increased to 34,000 (13). Over the same period (1994–2011), six serological surveys have been conducted, 2–3 years apart, to monitor trends in the HIV epidemic in adults aged 15 years and over in the population (14, 15). Dry blood spots are collected and two independent enzyme-linked immunosorbent assays are used, according to Tanzanian guidelines to determine those who are HIV positive.

Data management and statistical analysis
All data from community cohort were entered using Census and Surveys Processing (CSPro) software (U.S. Bureau of the Census & ORC Macro’s MEASURE DHS+ project, 2000), and transferred to STATA Version12 (Stata Corp., College Station, Texas) for analysis. ASMRs were calculated by dividing the number of deaths observed by the person years of follow-up, for each sex and 5-year age group in the resident population. Adult mortality was summarized as 45Q15, which is obtained by multiplying the survival derived from the ASMRs. The 45Q15 measure was obtained separately for males and females in the cohort, and based on the serological HIV status of those who had been tested, the 45Q15 measure was obtained for HIV-positive, HIV-negative and HIV-unknown groups. Parameters, ASME and 45Q15, estimated from the cohort data are shown with 95% confidence intervals (95% CI) derived from the Poisson distribution for deaths in this cohort.

The Spectrum model
The Spectrum model analyses existing country-specific data to estimate the current and future population structure and health of the people in the country. It comprises of different, integrated policy modules such as the Demographical Projection (DemProj), AIDS Impact (AIM), Family Planning (FamPlan), Child Survival (LIST) among others. Each module relies on programmatic input data and demographical information obtained from DemProj (which in turns bases its projection on data from the UN Population Division) to produce indicators for a given public health area.

AIM is at the root of the Spectrum estimates for HIV-attributable mortality. It consists of three independent sub-models: mother-to-child transmission, child HIV and
adult HIV. AIM projects the consequences of HIV incidence trends, including the number of people living with HIV, number of new infections, number of pregnant women infected with HIV, and mortality due to AIDS. It is widely used to forecast near-term treatment and prevention of mother-to-child transmission (PMTCT) needs. In addition to the role AIM plays in HIV program planning, it is also used to estimate the impact of HIV prevention programs, such as the impact of expanding PMTCT and ART programs.

The Spectrum model used the general patterns of the HIV epidemic in Tanzania, with changes to specifically model the age and sex structure in Kisesa. The specific input parameters to the Spectrum model were obtained from a workshop in 2012 with members of the network for Analysis of Longitudinal Population-based HIV data in Africa (ALPHA). Details of data analysis work by the ALPHA network are given by Maher et al. (16). The structure of the Spectrum modelling and the general parameters are described elsewhere (17).

**Ethical issues**

Individual informed consent was obtained from sero survey study participants. Research activities in the Kisesa cohort study were granted ethics approval by the Tanzanian National Research Ethics Review Sub-committee (NatREC) and the London School of Hygiene and Tropical Medicine (LSHTM) ethics committee.

**Results**

**Adult ASMRs**

Figure 1 shows the ASMRs for three periods (1994–1999, 2000–2004, 2005–2009). ASMRs per 1,000 person years among those aged 30–34 were 13.33 (95% CI: 10.75–16.52) in the period 1994–1999, 11.03 (95% CI: 8.84–13.77) in 2000–2004, and 6.22 (95% CI: 4.75–8.15) in 2005–2009. Overall all-cause mortality rates in Kisesa are lower in the period 2005–2009 than in previous periods for all age groups, although the 95% confidence intervals are wide and the differences for any age group may not be significant. In all periods, all-cause mortality increased with age, with ASMRs for three periods (1994–1999, 2000–2004 and 2005–2009) shown separately for men and women (Table 1). The Spectrum model showed that ASMRs for adults aged 30–49 years increased between the 1994–1999 period and the 2000–2004 period. For all ages the ASMRs decreased between 2000–2004 and 2005–2009.

45Q15 mortality trends

Table 2 shows time trends of the index of the proportion of adult deaths between 15 and 60 years of age (45Q15) by sex from the Kisesa DSS data, and the Spectrum model estimates. The probability of dying in the age group 15–60 has declined from the year 2000 for both sexes. The chance of dying in the 15–60 age group for both sexes combined was 39% (95% CI: 27–55%) in 1994 and 22% (95% CI: 15–31%) in 2009. Men were found to have a higher 45Q15 than women across all time periods, though the 95% confidence intervals overlap in each of the years. With ART introduction in 2005, there is a consistent decline in the 45Q15 measure over the next 5 years.

The Spectrum model showed an increase in the 45Q15 measure of mortality for both sexes from 43% in 1994 to 48% in 2000 and a subsequent decline to 37% in 2009. A similar pattern was shown for women and men separately, with men having a higher probability of dying than women across all periods of time. Figure 1 illustrates trends in the index of adult mortality (45Q15) by sex. The 45Q15 was generally higher in men compared to women except in a few years. The difference in 45Q15 measure of...
Table 1. Adult age-specific mortality rates per 1,000 person years (all-cause, men and women) from Kisesa cohort data and Spectrum model estimates

| Age group | Empirical data | Spectrum estimate | Empirical data | Spectrum estimate | Empirical data | Spectrum estimate |
|-----------|----------------|-------------------|----------------|-------------------|----------------|-------------------|
| Number of deaths | Number of person years | Mortality rate (95% CI) | Number of deaths | Mortality rate (95% CI) | Number of deaths | Mortality rate (95% CI) |
| Men       | 1994–1999     | 2000–2004         | 2005–2009       |
| 15–19     | 19            | 6,064             | 3.13 (2.49–4.91) | 19                | 6,275           | 3.03 (1.93–4.75)    | 15                | 7,654           | 1.96 (1.18–3.25) |
| 20–24     | 19            | 4,716             | 4.03 (2.57–6.32) | 17                | 5,029           | 3.38 (2.1–5.44)    | 20                | 5,229           | 3.82 (2.47–5.93) |
| 25–29     | 25            | 3,615             | 6.91 (4.67–10.23)| 24                | 4,089           | 5.87 (3.93–8.76)   | 31                | 4,165           | 7.44 (5.23–10.58)|
| 30–34     | 49            | 3,312             | 14.80 (11.18–19.58) | 32                | 3,344           | 9.57 (6.77–13.53)  | 48                | 4,096           | 6.84 (4.72–9.90) |
| 35–39     | 45            | 2,654             | 16.96 (12.66–22.71) | 33                | 2,922           | 11.30 (8.03–15.89) | 37                | 3,249           | 11.39 (8.25–15.72)|
| 40–44     | 21            | 1,903             | 11.04 (7.2–16.93) | 49                | 2,425           | 20.21 (15.27–26.47) | 49                | 2,744           | 11.30 (7.94–16.06)|
| 45–49     | 31            | 1,609             | 19.26 (13.55–27.39) | 31                | 1,688           | 18.36 (12.91–26.11) | 31                | 2,254           | 11.09 (7.49–16.41)|
| 50–54     | 25            | 1,333             | 18.76 (12.68–27.76) | 25                | 1,290           | 19.39 (13.1–28.69) | 31                | 1,563           | 19.83 (13.94–28.19)|
| 55–59     | 23            | 1,005             | 22.89 (15.21–34.44) | 25                | 1,093           | 21.95 (14.71–32.75) | 31                | 1,147           | 18.31 (11.94–28.08)|
| 60+       | 126           | 2,387             | 52.79 (40.33–69.79) | 138               | 2,500           | 55.20 (42.35–71.80) | 135               | 2,801           | 48.20 (36.34–63.88)|
| Women     | 1994–1999     | 2000–2004         | 2005–2009       |
| 15–19     | 10            | 5,265             | 1.90 (1.02–3.53)  | 19                | 5,774           | 3.29 (2.1–5.16)    | 17                | 6,881           | 2.47 (1.54–3.97)  |
| 20–24     | 35            | 4,954             | 5.65 (3.9–8.19)   | 28                | 4,954           | 5.65 (3.9–8.19)    | 30                | 5,310           | 1.88 (1.01–3.5)   |
| 25–29     | 35            | 4,164             | 8.40 (6.03–11.71) | 36                | 4,572           | 7.87 (5.87–10.92)  | 47                | 4,767           | 6.08 (4.23–8.75)  |
| 30–34     | 46            | 3,598             | 12.78 (9.58–17.07) | 46                | 3,728           | 12.34 (9.24–16.47) | 48                | 4,243           | 5.65 (3.82–8.37)  |
| 35–39     | 25            | 2,619             | 9.55 (6.45–14.13) | 40                | 3,164           | 12.64 (9.27–17.24) | 50                | 3,402           | 8.23 (5.68–11.92) |
| 40–44     | 22            | 2,059             | 10.69 (7.04–16.23) | 30                | 2,436           | 12.31 (8.61–17.61) | 29                | 2,995           | 8.35 (5.64–12.35) |
| 45–49     | 18            | 1,566             | 11.50 (7.24–18.25) | 21                | 1,884           | 11.15 (7.27–17.1)  | 23                | 2,379           | 9.67 (6.42–14.55) |
| 50–54     | 19            | 1,368             | 13.89 (8.86–21.78) | 20                | 1,406           | 14.22 (9.18–22.04) | 21                | 1,733           | 10.97 (6.99–17.19)|
| 55–59     | 19            | 1,079             | 17.62 (11.24–27.62) | 13                | 1,186           | 16.87 (10.88–26.14) | 18                | 1,363           | 13.21 (8.32–20.97)|
| 60+       | 151           | 2,866             | 52.69 (40.21–69.00) | 132               | 3,113           | 42.40 (36.31–48.81) | 139               | 3,612           | 38.48 (33.45–44.97)|
mortality between empirical data and the modelled estimate ranged from 0.03 to 0.16 among men and 0.01 to 0.17 among women. Figure 3 illustrates how the two data sources, which are empirical versus modelled data for index of adult mortality (45Q15) by sex and calendar year, compare to each other.

**Table 2.** Index of adult mortality (45Q15) by sex and calendar year from Kisesa cohort data and Spectrum model estimates

| Year | Men Empirical 45Q15 (95% CI) | Spectrum estimates | Difference\(^a\) | Women Empirical 45Q15 (95% CI) | Spectrum estimates | Difference\(^a\) | Both sexes Empirical 45Q15 (95% CI) | Spectrum estimates | Difference\(^a\) |
|------|-----------------------------|-------------------|-----------------|--------------------------------|-------------------|-----------------|---------------------------------|-------------------|-----------------|
| 1994 | 0.43 (0.26–0.63)            | 0.47              | 0.04            | 0.35 (0.18–0.61)               | 0.40              | 0.05            | 0.39 (0.27–0.55)               | 0.43              | 0.04            |
| 1995 | 0.30 (0.21–0.40)            | 0.48              | 0.18            | 0.43 (0.32–0.55)               | 0.41              | −0.02           | 0.36 (0.29–0.45)               | 0.45              | 0.09            |
| 1996 | 0.42 (0.32–0.53)            | 0.49              | 0.07            | 0.42 (0.31–0.54)               | 0.43              | 0.01            | 0.41 (0.34–0.49)               | 0.46              | 0.05            |
| 1997 | 0.53 (0.42–0.64)            | 0.50              | −0.03           | 0.36 (0.27–0.48)               | 0.44              | 0.08            | 0.45 (0.38–0.54)               | 0.47              | 0.02            |
| 1998 | 0.37 (0.27–0.50)            | 0.50              | 0.13            | 0.34 (0.23–0.48)               | 0.45              | 0.11            | 0.35 (0.28–0.44)               | 0.48              | 0.13            |
| 1999 | 0.58 (0.46–0.70)            | 0.50              | −0.08           | 0.34 (0.26–0.45)               | 0.46              | 0.12            | 0.47 (0.39–0.55)               | 0.48              | 0.01            |
| 2000 | 0.46 (0.35–0.57)            | 0.50              | 0.04            | 0.42 (0.34–0.51)               | 0.46              | 0.04            | 0.44 (0.37–0.51)               | 0.48              | 0.04            |
| 2001 | 0.42 (0.32–0.53)            | 0.49              | 0.07            | 0.39 (0.30–0.50)               | 0.46              | 0.07            | 0.41 (0.34–0.49)               | 0.48              | 0.07            |
| 2002 | 0.33 (0.24–0.44)            | 0.49              | 0.16            | 0.35 (0.27–0.45)               | 0.46              | 0.11            | 0.34 (0.28–0.41)               | 0.47              | 0.13            |
| 2003 | 0.45 (0.35–0.56)            | 0.48              | 0.03            | 0.35 (0.27–0.46)               | 0.46              | 0.11            | 0.40 (0.33–0.48)               | 0.47              | 0.07            |
| 2004 | 0.43 (0.34–0.54)            | 0.47              | 0.04            | 0.32 (0.24–0.43)               | 0.45              | 0.13            | 0.38 (0.32–0.45)               | 0.46              | 0.08            |
| 2005 | 0.40 (0.31–0.50)            | 0.46              | 0.06            | 0.36 (0.28–0.46)               | 0.44              | 0.12            | 0.38 (0.32–0.45)               | 0.45              | 0.07            |
| 2006 | 0.35 (0.26–0.47)            | 0.45              | 0.10            | 0.22 (0.14–0.32)               | 0.43              | 0.11            | 0.29 (0.22–0.36)               | 0.44              | 0.15            |
| 2007 | 0.46 (0.35–0.59)            | 0.43              | −0.03           | 0.31 (0.22–0.41)               | 0.40              | 0.09            | 0.38 (0.31–0.46)               | 0.41              | 0.03            |
| 2008 | 0.30 (0.21–0.41)            | 0.40              | 0.10            | 0.25 (0.16–0.36)               | 0.37              | 0.12            | 0.27 (0.20–0.34)               | 0.38              | 0.11            |
| 2009 | 0.26 (0.18–0.38)            | 0.38              | 0.12            | 0.18 (0.13–0.26)               | 0.35              | 0.17            | 0.22 (0.17–0.29)               | 0.37              | 0.15            |

\(^a\) 45q15 denotes probability of dying between 15–60 years of age.

\(^b\) CI denotes the 95% confidence intervals.

\(^c\) Difference = Spectrum 45Q15 minus Empirical 45Q15.

Adult mortality (45Q15) trends by HIV status

Figure 2 illustrates trends in 45Q15 by HIV status separately for men and women. The highest 45Q15 for men was reported in 1999 (58%, 95%CI: 46–70%) whilst the highest 45Q15 for women was in 2000 (42%, 95% CI: 34–51%). 45Q15 for HIV-positive adults was consistently higher than HIV-negative adults across all time periods. Adults with unknown sero status had higher 45Q15 than HIV-negatives but lower than HIV-positive adults. The trend was the same for both men and women. Although not conclusive, there was a downward trend of 45Q15 when both sexes were combined regardless of the sero status. This downturn was more pronounced among the HIV-positive females than among the HIV-positive males.

**Discussion**

Adult ASMRs in Kisesa peaked during the mid-1990s and declined during the periods from 2000 onwards. As expected ASMRs increased with increasing age, and the observed pattern of ASMRs corresponds to the expected mortality patterns in HIV infected adults (18). ART became available in Tanzania in 2005 through the care and treatment clinics (CTC) and the first members of the Kisesa cohort were referred to CTC in 2005. Uptake of ART in this cohort among those estimated to be in need of treatment has been estimated at less than 3% (19), but substantial declines in ASMRs have been seen, especially among adults aged 30–49 years. This is similar to the declines in ASMRs seen in other countries in sub-Saharan Africa following the introduction of ART (3).

The probability of dying between 15 and 60 years of age (45Q15) also showed a peak in the mid-1990s with a subsequent decrease of around 25% through to 2009. The agreement of the empirical data with the Spectrum model estimates for 45Q15 showed the expected epidemic curve for HIV peaking in the mid-1990s, and the larger declines from 2005 due to the introduction of ART in the community. This analysis shows good agreement between the outputs from the Spectrum model and the ASMRs and 45Q15 estimated from the empirical data using HIV serology. The model-based results for these measures of adult mortality in some population segments are smoothed, and the empirical results show variation from year to year, due to the relatively small numbers of deaths observed in this rural community cohort. Further work is needed to evaluate the model with community-based mortality data from other serological and verbal autopsy studies.

For the estimates of 45Q15 in this rural cohort, the agreement between the serological estimates and those
obtained from verbal autopsy using the Inter-VA4 software were less convincing. Whereas the serological data showed a marked drop in the proportion dying in 2005, after the introduction of ART, the verbal autopsy results showed little change after 2005 (C. Kanjala et al., unpublished data). In this supplement, Oti validates the Spectrum model against verbal autopsy data interpreted through Inter-VA4 in Nairobi and concludes that both HIV and TB deaths from the model need to be included to give an agreement with the Spectrum results (20). This may also be the reason for poor correlation between the empirical and Spectrum-modelled results in Kisesa.

In 2004, Stover et al. validated the Spectrum model estimates against empirical estimates of mortality from six population-based studies and concluded that the model performed well (21). However, there are few reports of validation of the Spectrum model against empirical serological data from populations in sub-Saharan Africa. A previous report noted that model-based approaches may over-estimate mortality due to HIV and may therefore over-estimate the decline in mortality with the introduction of ART (22).

In this analysis, estimated ASMRs in adults from the empirical data agreed well with the estimates from the Spectrum model. In particular, the decline in mortality seen in adults aged 30–49 years from 2005 onwards provides some evidence of the impact of ART in this population. A pooled analysis of population-based data in four selected sites in East and Southern Africa depicted a similar trend in adult mortality, which is greatly influenced by the introduction of ART in these areas (3, 19, 23). These results suggest that mortality trends and patterns may have been adequately modelled and predicted by the Spectrum model.

**Fig. 2.** Index of adult mortality by HIV status and calendar year with 95% confidence intervals.

**Fig. 3.** Index of adult mortality (45Q15) by sex and calendar year from Kisesa cohort data and Spectrum model estimates.
The observed data on the probability of dying between 15 and 60 years of age in this analysis were similar to the estimates from a population-based study in Uganda. In Uganda, the $45Q_{15}$ before 2004 was estimated as 51% for men (95% CI: 45–57%) and 44% for women (95% CI: 39–49%), decreasing from 2005 onwards, to 38% (95% CI: 33–44%) for men and 32% (95% CI: 28–37%) for women (3). Although there was a slightly higher overall estimate of $45Q_{15}$ in Uganda compared to these results, there is a consistent trend in a decreasing $45Q_{15}$ following the introduction of ART.

A comparison of the $45Q_{15}$ estimates for those known to be HIV positive reinforces the conclusion that mortality has decreased, and that a greater decrease has been observed in women than men. From 2005, empirical data show that the $45Q_{15}$ in women has been declining, indicating that survival in those that are HIV positive has improved. It is not surprising that women have shown greater improvements in survival, as it has been shown that women are more likely to access ART relative to estimated need for treatment and that they access ART with higher CD4 counts and better immunological status (24).

The data for this paper have been taken from demographic surveillance of vital events in 30,000 people since 1994. With less than 100 deaths per annum between the ages of 15 and 60 years, there is considerable variation in the annual adult mortality. Previous studies have shown that epidemiological models may over-estimate mortality due to HIV/AIDS, although some deaths may have been missed from this study due to out-migration. We have presented the data on ASMRs and $45Q_{15}$ in this paper, and have not shown age adjusted mortality rates, as the population structure in Kisesa has not changed much over the 19 years of follow-up, and the age adjusted adult mortality rate is very similar to the $45Q_{15}$ that we present.

Although the size of the decline in all-cause mortality may differ between the model and the observed data, the decline from pre-ART to post-ART periods is clear from both the data and the model outputs.

**Conclusion**

Most resource-limited countries lack vital registration data, in order to estimate mortality rates and other demographic population parameters. This article presents a fair comparison of mortality estimates generated by the Spectrum model against empirical data from a long-standing population-based cohort. From 1994 to 2009, the observed decrease in ASMRs was steeper in younger age groups than that predicted by the Spectrum model perhaps because the Spectrum model under-estimated the ASMRs in 30–34 year olds in 1994–99. However, the Spectrum model predicted a greater decrease in $45Q_{15}$ mortality than observed in the cohort, although the reasons for this over-estimate are unclear. These findings have evidently shown a technical gap to be filled to improve the Spectrum model such that it can exactly predict population parameters in setting where empirical data are scarce but they are needed for health planning.

**Acknowledgement**

We acknowledge the many staff in the TAZAMA project who work on the demographic surveillance in Kisesa. We also thank the survey participants for their continued participation in the demographic surveillance. This work came out of collaborative analysis led by the ALPHA network facilitators, and we are grateful for the contribution that the ALPHA network has made through the workshops and subsequent help in the analysis and writing up of this paper. We acknowledge the help from Futures Institute and Mary Mahy (UNAIDS) in initiating the Spectrum analysis and for providing helpful advice on the manuscript.

**Authors’ contributions**

DM wrote the first draft of the manuscript, collected and analysed the data, CK analysed the data and contributed to the writing of the manuscript, CP ran the Spectrum model analyses and contributed to writing of the manuscript, CC analysed the data and contributed to the writing of the manuscript, JT analysed the data and contributed to the writing of the manuscript, AW reviewed the first draft and commented on the subsequent drafts of the manuscript, BM organized the data collection and management, and commented on the manuscript, RI analysed the data and commented on the manuscript, BZ provided the scientific ideas and the demographic rigor for the paper, and commented on the manuscript and MU led the project, contributed to the scientific ideas and commented on the manuscript.

**Conflict of interest and funding**

The analysis for this paper was funded through the ALPHA network from the Wellcome Trust to LSHTM, grant reference number 090959/Z/09/Z.

**References**

1. National Bureau of Statistics, Tanzania. Tanzania demographic and health, 2010 survey. TZA-NBS-DHS-2010-V01. Available from: http://www.nbs.go.tz/tnada/index.php/catalog/12 [cited 14 September 2013].

2. Urassa M, Boerma JT, Isingo R, Ngalula J, Ng J, Mwaluko G et al. The impact of HIV/AIDS on mortality and household mobility in rural Tanzania. AIDS 2001; 15: 2017–23.

3. Floyd S, Marston M, Baisley K, Wringe A, Herbst K, Chihana M, et al. The effect of antiretroviral therapy provision on all-cause, AIDS and non-AIDS mortality at the population level – a comparative analysis of data from four settings in Southern and East Africa. Trop Med Int Health 2012; 17: e84–93.

4. Kasamba I, Baisley K, Mayanja BN, Maher D, Grosskurth H. The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999–2009. Trop Med Int Health 2012; 17: e66–73.

5. World Bank. Adult mortality rates by country 1980–2012. Available from: http://data.worldbank.org/indicator/SP.DYN.AMRT.CA [citied 14 September 2013].

Citation: Glob Health Action 2014, 7: 21783 - http://dx.doi.org/10.3402/gha.v7.21783
6. Chihana M, Floyd S, Molesworth A, Crampin AC, Kayuni N, Price A, et al. Adult mortality and probable cause of death in rural northern Malawi in the era of HIV treatment. Trop Med Int Health 2012; 17: e74–83.
7. Todd J, Balira R, Grosskurth H, Mayaud P, Mosha F, Klokke A, et al. HIV-associated adult mortality in a rural Tanzanian population. AIDS 1997; 11: 801–7.
8. Dzekedzeka K, Siziya S, Fylkesnes K. The impact of HIV infection on adult mortality in some communities in Zambia: a cohort study. Trop Med Int Health 2008; 13: 152–61.
9. Lopman BA, Barnabas RV, Boerma JT, Chawira G, Gaitseki K, Harrop T, et al. Creating and validating an algorithm to measure AIDS mortality in the adult population using verbal autopsy. PLoS Med 2006; 3: e312.
10. Marston M, Michael D, Wringe A, Isingo R, Clark BD, Jonas A, et al. The impact of antiretroviral therapy on adult mortality in rural Tanzania. Trop Med Int Health 2012; 17: 58–65.
11. Ghys PD, Brown T, Grassly NC, Garnett G, Stanecki KA, Stover J, et al. The UNAIDS estimation and projection package: a software package to estimate and project national HIV epidemics. Sex Transm Infect 2004; 80: i5–9.
12. Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect 2012; 88: i11–i16.
13. National Bureau of Statistics, Tanzania. 2012 Population and housing census population distribution by administrative units. Available from: http://www.nbs.go.tz/sensa/PDF/2012%20PHC%20POPULAR%20VERSION.pdf [cited 14 September 2013].
14. Isingo R, Wringe A, Todd J, Urassa M, Mbata D,Maiseli G et al. Trends in the uptake of voluntary counselling and testing for HIV in rural Tanzania in the context of the scale up of antiretroviral therapy. Trop Med Int Health 2012; 17: e15–25.
15. Wambura M, Urassa M, Isingo R, Ndege M, Marston M, Slaymaker E, et al. HIV prevalence and incidence in rural Tanzania: results from 10 years of follow-up in an open-cohort study. J Acquir Immune Defic Syndr 2007; 46: 616–23.
16. Maher D, Biraro S, Hosegood V, Isingo R, Lutalo T, Mushati P, et al. Translating global health research aims into action: the example of the ALPHA network. Trop Med Int Health 2010; 15: 321–8.
17. Futures Institute. About Spectrum. Available from: http://www.futuresinstitute.org/spectrum.aspx [cited 28 October 2013].
18. Mulder DW, Nunn AJ, Wagner HU, Kamali A, Kengeya-Kayondo JF. HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort. AIDS 1994; 8: 87–92.
19. Wringe A, Floyd S, Kazooba P, Mushati P, Baisley K, Urassa M, et al. Antiretroviral therapy uptake and coverage in four HIV community cohort studies in sub-Saharan Africa. Trop Med Int Health 2012; 17: e38–48.
20. Ota S, Wamukoya M, Mahy M, Kyobutungi C. InterVA versus Spectrum: how comparable are they in estimating AIDS mortality patterns in Nairobi’s informal settlements? Glob Health Action 2013; 6: 21638.
21. Stover J, Ghys PD, Walker N. Testing the accuracy of demographic estimates in countries with generalized epidemics. AIDS 2004; 18: S67–73.
22. Fazito E, Cuchi P, Fat DM, Ghys PD, Pereira MG, Vasconcelos AMN, et al. Identifying and quantifying misclassified and under-reported AIDS deaths in Brazil: a retrospective analysis from 1983 to 2009. Sex Transm Infect 2012; 88: i86–i94.
23. Herbst AJ, Mafojane T, Newell ML. Verbal autopsy-based cause-specific mortality trends in rural KwaZulu-Natal, South Africa, 2000–2009. Popul Health Metr 2011; 9: 47.
24. Somi G, Keogh SC, Todd J, Kilama B, Wringe A, Hombergh JVD, et al. Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme. Trop Med Int Health 2012; 17: 497–506.